Therapeutic effect of Xinmailong combined trimetazidine on chronic heart failure / 心血管康复医学杂志

ABSTRACT

Objective:To explore therapeutic effect of Xinmailong combined trimetazidine on patients with chronic heart failure (CHF).Methods:A total of 155 CHF inpatients hospitalized in our department from Oct 2013 to Apr 2016 were selected.According to therapeutic method,patients were divided into routine treatment group (n＝50),Xinmailong group (n＝52,received Xinmailong injection based on routine treatment group ) and combined treatment group (n＝53,received trimetazidine based on Xinmailong group ),all groups were treated for eight weeks.Stroke volume (SV),cardiac output (CO),cardiac index (CI),left ventricular ejection fraction (LVEF),transmitral early diastolic peak flow velocity/late diastolic peak flow velocity (E/A),6min walking distance (6MWD) and total ef-fective rate were measured and compared among three groups before and after treatment.Results:Total effective rate of combined treatment group was significantly higher than that of routine treatment group (88.7% vs.66.0%,P＝0.006),but there were no significant difference between combined treatment group and Xinmailong group (P＝0.171).Compared with before treatment,after eight-week treatment,there were significant rise in SV,CO,CI,LVEF,E/A and 6MWD in three groups,P＝0.001 all.Compared with routine treatment group after eight-week treatment,there were significant rise in SV,CI,LVEF and 6MWD in Xinmailong group,P＜0.01 all;compared with routine treatment group and Xinmailong group,there were significant rise in SV [ (48.6 ± 8.9) ml vs.(53.6 ± 8.5) ml vs.(60.2 ± 8.4) ml],CO [ (4.4 ± 0.5) L/min vs.(4.5 ± 0.6) L/min vs.(5.7 ± 0.6) L/min],CI [ (3.1 ± 0.9) L·min-1·m-2vs.(3.7 ± 0.3) L·min-1·m-2vs.(4.3 ± 0.4) L·min-1·m-2],LVEF [ (42.3 ± 8.4)% vs.(46.6 ± 7.9)% vs.(53.2 ± 7.3)%],E/A [ (1.0 ± 0.3) vs.(1.1 ± 0.3) vs.(1.4 ± 0.2)] and 6MWD [ (342.88 ± 52.44) m vs.(420.90 ± 36.86) m vs.(443.55 ± 25.30) m] in combined treatment group,P＝0.001 all.Conclusion:Xinmailong combined trimetazidine can improve cardiac function,hemodynamics,ventricular re-modeling and therapeutic effect in patients with chronic heart failure.